Evaluation of the nonparametric estimation method in nonmem VI: application to real data

The aim of the study was to evaluate the nonparametric estimation methods available in NONMEM VI in comparison with the parametric first-order method (FO) and the first-order conditional estimation method (FOCE) when applied to real datasets. Four methods for estimating model parameters and parameter distributions (FO, FOCE, nonparametric preceded by FO (FO-NONP) and nonparametric preceded by FOCE (FOCE-NONP)) were compared for 25 models previously developed using real data and a parametric method. Numerical predictive checks were used to test the appropriateness of each model. Up to 1000 new datasets were simulated from each model and with each method to construct 90% and 50% prediction intervals. The mean absolute error and the mean error of the different outcomes investigated were computed as indicators of imprecision and bias respectively and formal statistical tests were performed. Overall, less imprecision and less bias were observed with nonparametric methods than with parametric methods. Across the 25 models, t-tests revealed that imprecision and bias were significantly lower (P < 0.05) with FOCE-NONP than with FOCE for half of the NPC outcomes investigated. Improvements were even more pronounced with FO-NONP in comparison with FO. In conclusion, when applied to real datasets and evaluated by numerical predictive checks, the nonparametric estimation methods in NONMEM VI performed better than the corresponding parametric methods (FO or FOCE).

[1]  Mats O. Karlsson,et al.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial , 2003, European Journal of Clinical Pharmacology.

[2]  D. B. White,et al.  An evaluation of point and interval estimates in population pharmacokinetics using Nonmem analysis , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  Mats O. Karlsson,et al.  Mechanism-based pharmacokinetic and pharmacodynamic modelling of tesaglitazar in type 2 diabetes patients , 2006 .

[4]  Mats O Karlsson,et al.  Application of population pharmacokinetics to cladribine , 2005, BMC pharmacology.

[5]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  M O Karlsson,et al.  Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone , 1998, Clinical pharmacology and therapeutics.

[7]  A. Mallet A maximum likelihood estimation method for random coefficient regression models , 1986 .

[8]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Alain Durand,et al.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  Grant Langdon,et al.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients , 2006, European Journal of Clinical Pharmacology.

[11]  Mats O Karlsson,et al.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. , 2008, British journal of clinical pharmacology.

[12]  R. Tibshirani,et al.  Generalized Additive Models , 1991 .

[13]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.

[14]  R. Tibshirani,et al.  Generalized additive models for medical research , 1986, Statistical methods in medical research.

[15]  L Aarons,et al.  Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.

[16]  M. Karlsson,et al.  Population pharmacokinetic‐pharmacodynamic modeling of moxonidine using 24‐hour ambulatory blood pressure measurements , 1998, Clinical pharmacology and therapeutics.

[17]  Michel Tod,et al.  Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Djalil Chafaï,et al.  Comparison of nonparametric methods in nonlinear mixed effects models , 2009, Comput. Stat. Data Anal..

[19]  Mats O. Karlsson,et al.  Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  M O Karlsson,et al.  Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. , 1997, British journal of clinical pharmacology.

[21]  Robert Leary,et al.  Parametric and Nonparametric Population Methods , 2006, Clinical pharmacokinetics.

[22]  France Mentré,et al.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  Andrew C. Hooker,et al.  Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method , 2007, Pharmaceutical Research.

[24]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[25]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[26]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  R. Savic,et al.  Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults , 2006, Journal of clinical pharmacology.

[29]  A Schumitzky,et al.  Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. , 2000, Therapeutic drug monitoring.

[30]  M O Karlsson,et al.  Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. , 2001, British journal of clinical pharmacology.

[31]  Mats O Karlsson,et al.  Evaluation of the nonparametric estimation method in NONMEM VI. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  Manuel Hidalgo,et al.  CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. , 2006, Journal of the National Cancer Institute.

[33]  Mats O. Karlsson,et al.  Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions , 2009, The AAPS Journal.

[34]  Mats O. Karlsson,et al.  Ximelagatran in extended secondary prevention of venous thromboembolism: Pharmacokinetics, pharmacodynamics and relationships to clinical events , 2006 .

[35]  Mats O Karlsson,et al.  Population pharmacokinetics of levosimendan in patients with congestive heart failure. , 2003, British journal of clinical pharmacology.

[36]  Roger W. Jelliffe,et al.  An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models , 2001, Proceedings 14th IEEE Symposium on Computer-Based Medical Systems. CBMS 2001.